Undisclosed CAR-NK therapies for solid tumors / Catamaran Bio - LARVOL DELTA

Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors (Businesswire) - "Catamaran Bio...is presenting new preclinical data today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held in Washington, DC....CAR-NK cells engineered with this TGFβ DNR demonstrated reduction of downstream TGFβ activity as shown by >90% reduction of SMAD2 phosphorylation (a downstream signal of TGFβ activity) even at supraphysiological doses of TGFβ....Chronic TGFβ stimulation strengthened NK cell tumor killing and target-induced cytokine secretion, and incorporation of the switch receptors also protected the cells from suppressive TGFβ signaling."

Preclinical • Oncology • Solid Tumor

Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors (Businesswire) - "Catamaran Bio...announced that the company will present two posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held in Washington, DC, on May 16-18, 2022. Catamaran scientists will present data supporting CAR‑NK cell therapy design strategies to neutralize the immunosuppressive effects of the tumor microenvironment, including use of synthetic biology-enabled chimeric switch receptors which convert the inhibitory signal of TGF-β into positive NK cell activation signals."

Preclinical • Oncology • Solid Tumor